Payment overview · 2025
General Payments
$39.61
2 reported records · 2 companies
Healthcare provider profile · identity verified
Hasan Imanli, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1205325628
Verified facts
What the public records show
CMS Open Payments records show Hasan Imanli, MD received $39.61 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 63.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.98 | 63.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.63 | 36.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $24.98 | 1 |
| Education | $14.63 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 766 | 106 |
| Eliquis | Apixaban | 749 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 58 |
| Jardiance | Empagliflozin | 334 | 22 |
| Divalproex Sodium | Divalproex Sodium | 288 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 36 |
| Mirtazapine | Mirtazapine | 253 | 38 |
| Gabapentin | Gabapentin | 251 | 40 |
| Carvedilol | Carvedilol | 239 | 32 |
| Metformin Hcl | Metformin Hcl | 235 | 31 |
| Furosemide | Furosemide | 204 | 41 |
| Trazodone Hcl | Trazodone Hcl | 183 | 25 |
| Lisinopril | Lisinopril | 181 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 32 |
| Losartan Potassium | Losartan Potassium | 157 | 23 |
| Sertraline Hcl | Sertraline Hcl | 157 | 26 |
| Levetiracetam | Levetiracetam | 149 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 30 |
| Trulicity | Dulaglutide | 145 | suppressed |
| Nifedipine Er | Nifedipine | 143 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 21 |
| Farxiga | Dapagliflozin Propanediol | 134 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 20 |
| Entresto | Sacubitril/Valsartan | 124 | suppressed |
| Aripiprazole | Aripiprazole | 122 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 18 |
| Xarelto | Rivaroxaban | 118 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 22 |
| Januvia | Sitagliptin Phosphate | 105 | suppressed |
| Potassium Chloride | Potassium Chloride | 96 | 31 |
| Latanoprost | Latanoprost | 91 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 15 |
| Omeprazole | Omeprazole | 80 | 16 |
| Baclofen | Baclofen | 79 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 11 |
| Allopurinol | Allopurinol | 75 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 20 |
| Donepezil Hcl | Donepezil Hcl | 70 | suppressed |
| Olanzapine | Olanzapine | 67 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 66 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 11 |
| Ozempic | Semaglutide | 63 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 60 | suppressed |
| Tradjenta | Linagliptin | 60 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Famotidine | Famotidine | 58 | 12 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 50 | 24 |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 47 | 47 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 47 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 21 |
| Benztropine Mesylate | Benztropine Mesylate | 44 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 41 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Nystatin | Nystatin | 39 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 14 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 30 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Tetrabenazine | Tetrabenazine | 28 | suppressed |
| Glatopa | Glatiramer Acetate | 26 | suppressed |
| Insulin Aspart | Insulin Aspart | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Constulose | Lactulose | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 13 |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Humira(Cf) Pen | Adalimumab | 24 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Clozapine | Clozapine | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Atenolol | Atenolol | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Mitigare | Colchicine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39.61 · 2 records | Novo Nordisk Inc | REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error